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Abstract
Background: ARNT, a member of the basic helix-loop-helix family of transcription factors, is
located on human chromosome 1q21–q24, a region which showed well replicated linkage to type
2 diabetes. We hypothesized that common polymorphisms in the ARNT gene might increase the
susceptibility to type 2 diabetes through impaired glucose-stimulated insulin secretion.
Methods: We selected 9 single nucleotide polymorphisms to tag common variation across the
ARNT gene. Additionally we searched for novel variants in functional coding domains in European
American and African American samples. Case-control studies were performed in 191 European
American individuals with type 2 diabetes and 187 nondiabetic European American control
individuals, and in 372 African American individuals with type 2 diabetes and 194 African American
control individuals. Metabolic effects of ARNT variants were examined in 122 members of 26
European American families from Utah and in 225 unrelated individuals from Arkansas. Gene
expression was tested in 8 sibling pairs discordant for type 2 diabetes.
Results: No nonsynonymous variants or novel polymorphisms were identified. No SNP was
associated with type 2 diabetes in either African Americans or European Americans, but among
nondiabetic European American individuals, ARNT SNPs rs188970 and rs11204735 were associated
with acute insulin response (AIRg; p =< 0.005). SNP rs2134688 interacted with body mass index to
alter  β-cell compensation to insulin resistance (disposition index; p = 0.004). No significant
difference in ARNT mRNA levels was observed in transformed lymphocytes from sibling pairs
discordant for type 2 diabetes.
Conclusion: Common ARNT variants are unlikely to explain the linkage signal on chromosome 1q,
but may alter insulin secretion in nondiabetic subjects. Our studies cannot exclude a role for rare
variants or variants of small (< 1.6) effect size.
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Background
Type 2 diabetes mellitus is a complex heterogeneous
group of metabolic conditions characterized by elevated
levels of serum glucose. Impairment in both hepatic and
peripheral insulin action, and defective pancreatic insulin
secretion characterize fully developed type 2 diabetes. The
interaction between genetic risk factors and environmen-
tal or lifestyle factors likely account for the current rising
prevalence of type 2 diabetes among many populations,
including United States European Americans and African
Americans [1].
Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT,
also known as hypoxia inducible factor-1β) is a member
of the basic helix-loop-helix Per/AhR/ARNT/Sim (bHLH-
PAS) family of transcription factors. ARNT and its interact-
ing partners HIF1α, HIF2α, and AhR form heterodimeric
complexes which are required for cellular responses to
hypoxia and environmental toxins such as dioxin. ARNT
complexes also directly regulate the expression of genes
involved in glucose transport and glucose metabolism [2].
Recently, Gunton et al [3] implicated ARNT directly in
impaired insulin secretion in type 2 diabetes by showing
a 90% decrease ARNT messenger RNA in islets from dia-
betic individuals when compared to normal islets. Down-
regulation of ARNT  expression decreased the glucose
stimulated insulin secretion in the Min 6 β-cell line, and
mice lacking β-cell ARNT expression exhibited abnormal
glucose tolerance, impaired glucose stimulated insulin
secretion, and changes in islet gene expression similar to
human type 2 diabetes [3]. These studies have implicated
ARNT in the transcriptional regulation of genes required
for optimal glucose-responsive insulin secretion, and thus
suggest ARNT as a strong candidate gene for diabetes. A
further role of ARNT in type 2 diabetes is suggested by its
role as an obligate partner of several transcription factors
involved in the response to toxins and hypoxic stress [4].
Hence, ARNT may integrate the genetic predisposition to
β-cell failure [5] with environmental insults leading to
diabetes pathogenesis.
The  ARNT  gene is located on human chromosome
1q21.2, a region with well replicated linkage to type 2 dia-
betes by us in European American and African American
populations, and by others in European American, Chi-
nese, and Pima Indian populations [6]. Thus, in addition
to being a strong functional candidate, ARNT is a strong
positional candidate gene for type 2 diabetes. We hypoth-
esized that common polymorphisms in the ARNT gene
would alter its function or expression, and in turn increase
the susceptibility to diabetes by affecting glucose-stimu-
lated insulin secretion. We evaluated the association of
common ARNT sequence variants with type 2 diabetes by
using HapMap phase2 linkage disequilibrium informa-
tion [7] as well as by screening putative functional regions
of the gene for sequence variants in European American
and African American subjects, and by testing these vari-
ants for an association with type 2 diabetes. To examine
the physiologic impact of ARNT variants, we studied 352
non-diabetic subjects who had undergone frequently
sampled intravenous glucose tolerance tests, including
members of families ascertained in Utah and unrelated
European American subjects ascertained in Arkansas. We
also examined ARNT  expression in transformed lym-
phocytes as a surrogate tissue using a discordant sib pair
design, and we searched for additional evidence for cis-
acting regulatory sequence polymorphisms that would
alter the mRNA expression ratio between ARNT alleles.
Methods
Study subjects
Phenotypic features of our study populations are summa-
rized in the Table 1. Case-control studies with type 2 dia-
betes were conducted primarily in two samples: a
European American cohort of 191 diabetic subjects and
187 control subjects, and in an African-American cohort
of 372 type 2 diabetic patients and 194 control individu-
als. European American individuals were ascertained in
Utah for Northern European ancestry, as described previ-
ously [8,9], with additional control individuals ascer-
tained in Arkansas for similar criteria. All African
American individuals were ascertained in Arkansas. For all
case-control cohorts, individuals with diabetes had
known type 2 diabetes on pharmacological therapy, or
had a documented high fasting glucose or diabetic glucose
tolerance test. All diabetic individuals and had at least one
Table 1: Summary of Study Populations
Population Description Male/Female BMI(Kg/m2) Age(years) Diagnosis age
Utah Caucasian case/control cohort1 Control 72/115 27.5 (18.5,41.1) 51.0 ± 15.3 ---
Case 134/57 31.1 (21.9,44.2) 61.7 ± 10.7 51.5 ± 12.1
AR Caucasian case/control cohort2 Control 65/105 28.1 (19.1, 41.2) 41.0 ± 14.4 ---
Case 166/74 31.78 (21.7, 46.5) 60.5 ± 12.2 49.9 ± 12.8
African American case/control cohort Control 96/98 29.5 (18.8,46.3) 42.8 ± 13.3 ---
Case 198/174 32.0 (20.8, 49.4) 54.8 ± 12.5 42.8 ± 11.9
Utah Caucasian metabolic Family based non-diabetic 50/72 27.5 (18.3,41.3) 39.3 ± 10.5 ---
AR Caucasian metabolic Population based non-diabetic 81/149 29.4 (19.8, 43.7) 37.2 ± 9.5 ---BMC Medical Genetics 2008, 9:16 http://www.biomedcentral.com/1471-2350/9/16
Page 3 of 12
(page number not for citation purposes)
other first degree relative with type 2 diabetes. Non-dia-
betic control individuals had no history of diabetes in a
first degree relative and had either a normal 75 g oral glu-
cose tolerance test or a normal fasting glucose level
(below 5.6 mM). Replication of case-control association
was performed in a European American cohort of 240
T2DM and 170 control subjects ascertained in Arkansas
for similar selection criteria. Because of some overlap in
controls with the initial case control study, the combined
study size was 315 controls and 429 cases. All of our case
individuals were recruited from diabetes clinics. African
American diabetic individuals were recruited in large part
from Department of Veterans Affairs diabetes clinics,
resulting in a predominance of male diabetic individuals.
Control individuals were recruited from spouses or family
members of cases, by public advertisement, and by flyers
posted in hospitals, clinics, and other public locations.
Many control subjects were participants in other ongoing
studies that recruited nondiabetic subjects without a fam-
ily history of diabetes. Because female volunteers are in
excess in most studies, our control population was skewed
toward women whereas our case population was skewed
toward men.
Metabolic effects of ARNT sequence polymorphisms were
studied in two nondiabetic populations: a family based
cohort of 122 non-diabetic members from 26 families of
Northern European descent ascertained in Utah [10,11],
and a European American population of 225 unrelated
nondiabetic subjects ascertained in Arkansas with age
under 60 years. All Utah family members underwent a
tolbutamide – modified, frequently sampled intravenous
glucose tolerance test (FSIGT). Because tolbutamide
became unavailable during the study, 100 subjects had
tolbutamide modified tests, whereas the remainder had
an insulin modified (0.04 unit/kg) FSIGT [11]. All sub-
jects provided written, informed consent under a protocol
approved by the Institutional Review Board of either the
University of Utah Health Sciences Center or the Univer-
sity of Arkansas for Medical Sciences.
Genetic analysis
The  ARNT  gene spans ~67 kb of human
chromosome1q21.2 and consists of 22 exons (Figure 1).
We examined 74 single nucleotide polymorphisms
(SNPs) from the August 2006 HapMap data [7] for the
ARNT gene and 2 kb of surrounding sequence. We identi-
fied 17 SNPs that were both polymorphic and had minor
allele frequencies over 5%, from which we selected 9 tag-
SNPs using the TAGGER program as implemented in
HaploView 3.2 [12] with parameters of r2 ≤ 0.9 (see Figure
2). Similarly, from 75 HapMap SNPs reported in the Yoru-
ban population of West Africa (Nigerian), we identified
18 SNPs that were both polymorphic and had a minor
allele frequency exceeding 5% (Figure 3). We forced the
inclusion of the 3 SNPs that were also polymorphic in
European Americans, and identified an additional 7 tag-
SNPs (r2 ≤ 0.9, TAGGER program) to cover common vari-
ation in the ARNT  gene in an African-American
population (Figures 2 and 3). SNPs were genotyped by
Pyrosequencing (PSQ96, Biotage AB, Uppsula, Sweden)
using a modification of manufacturer's protocol that used
a biotinylated universal primer [9]. SNPs showing an
association with type 2 diabetes in the initial Northern
European case-control cohort were genotyped in a con-
firmatory Arkansas European American case-control
cohort. Associated SNPs and any SNPs with a minor allele
frequency over 10% in European Americans were also
tested for an association with quantitative prediabetic
traits in non-diabetic individuals.
Screening for novel variants
Given the large size of the ARNT gene, we focused the
screening for novel variants on the known major func-
Structure of the ARNT gene and location of SNPs analyzed Figure 1
Structure of the ARNT gene and location of SNPs analyzed. The approximate location of all 22 reference sequence 
exons is shown as black bars, and the large variable 3'UTR region is shown as hatched box. The location of the SNPs is shown 
as arrows below the schematic. Linkage disequilibrium relationships are shown in Figure 2 and 3.BMC Medical Genetics 2008, 9:16 http://www.biomedcentral.com/1471-2350/9/16
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tional domains: the DNA binding basic helix loop helix
(bHLH) domain (amino acid residues 103–143); the
dimerization (PAS) domain (amino acid residues 161–
235 and 349–419); and the transactivation domain at the
carboxyl terminal. Primers were designed for amplicons
of under 600 bp using sequence NM_001668 and the
University of California Santa Cruz (genome.ucsc.edu)
genome and proteome browsers for exons 1 (amino ter-
minal), 6 (bHLH domain), 7 (PAS domain 1), 12–13
(PAS domain 2), and 22 (transactivation domain). Addi-
tionally, the flanking intronic sequences, 5' untranslated
region, and 272 bp of the 3' untranslated region were
screened. Fragments were screened using denaturing high-
performance liquid chromatography (DHPLC) on a
Transgenomic WAVE HT DNA fragment analysis system
(Transgenomic Inc., Omaha, NE) in 24 European Ameri-
can and 24 African American individuals, each popula-
tion comprising 16 diabetic and 8 nondiabetic
participants. Variant chromatographic patterns were char-
acterized by dideoxy DNA sequencing. The 2 kb region 5'
to the transcription start site, which was non amenable to
DHPLC screening, was sequenced directly in the same 48
individuals (Polymorphic DNA Technologies, Inc.;
Alameda, CA).
Gene expression
Transformed lymphocytes from 8 sibling pairs discordant
for type 2 diabetes were grown under normoglycemic (5.6
mM glucose) conditions, then exposed to either 5.6 mM
glucose, or 28 mM glucose and 5 nM insulin for 8 hours
before harvest. Total RNA was extracted using RNEasy
mini kit (Qiagene Inc., Valancia, CA), the quantity and
Linkage disequilibrium pattern of the ARNT region based on HapMap data Figure 2
Linkage disequilibrium pattern of the ARNT region based on HapMap data. Markers selected for genotyping in our 
case-control cohorts are marked by an asterisk (*). The top portion of each diagram shows the known exon-intron structure. 
Only SNPs with a minor allele frequency over 5% in HapMap data were selected to construct the linkage disequilibrium map. 
Figure 2 shows linkage disequilibrium based on the r2 statistic using Hapmap Caucasian (CEPH) data.BMC Medical Genetics 2008, 9:16 http://www.biomedcentral.com/1471-2350/9/16
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quality checked using an Agilent 2100 Bioanalyzer, and
600 ng reverse transcribed using random hexamer primers
(TaqMan Reverse Transcription Reagents, Applied Biosys-
tems, Inc). ARNT expression was measured by real time
PCR on a Rotorgene 2000 Real time-PCR system (Corbett
Life Science, Sydney Australia), with 18S ribosomal RNA
as a normalization standard. Primer sequences were as
follows: 18S forward: ATCAACTTTCGATGG TAGTCG,
18S reverse: TCCTTGGATGTGGTAGCCG, ARNT – For-
ward: TTCATCCCATACTCAAAATACCC, ARNT – Reverse:
AAAGCAAAACCCAATCTCAA.
Allelic expression imbalance
Unequal expression of ARNT alleles was sought as evi-
dence for cis acting regulatory variants by comparing peak
heights in individuals heterozygous for the synonymous
coding SNP rs2228099 or 3' untranslated SNP rs10847,
using methods described elsewhere [13]. Briefly, total
RNA was reverse transcribed using random hexamers.
Allelic specific quantitation of both cDNA and genomic
DNA samples was determined using the same assay for
pyrosequencing on a PSQ 96 Pyrosequencer (Biotage, Inc,
Uppsala, Sweden), with peak height quantified using
Allele Quantification software (Biotage, Inc).
Statistical analysis
Allele frequencies in case and control populations were
compared using Fisher Exact and Cochran-Armitage
Trend tests. Hardy-Weinberg equilibrium was tested using
the online DeFinetti program [14]. Linkage Disequilib-
rium and haplotype association analyses were performed
by Haploview v. 3.32 [12]. Insulin secretion was calcu-
lated as the acute insulin response to glucose (AIRg),
determined either as the mean excursion over baseline
Linkage disequilibrium pattern of the ARNT region based on HapMap data in Yorubans Figure 3
Linkage disequilibrium pattern of the ARNT region based on HapMap data in Yorubans. Figure 3 is identical to 
Figure 2, except shown in Yorubans for selection of SNPs in African Americans. Asterisks (*) identify markers selected for gen-
otyping.BMC Medical Genetics 2008, 9:16 http://www.biomedcentral.com/1471-2350/9/16
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from 2–10 min (Utah population) or the 2 min – 10 min
Area Under Curve (AUC; Arkansas population). Although
they give different values, the two methods of computing
AIRgare highly correlated. Insulin sensitivity (SI) was cal-
culated from the FSIGT using either the MinMod (Utah
sample) or MinMod Millenium (Arkansas Sample) pro-
grams [15,16]. The two programs use the same algorithms
and provide nearly identical estimates of SI. The ability of
the β-cell to compensate for insulin sensitivity was deter-
mined by the disposition index (DI = SI *AIRg) [17,18].
Genotypic effects on glucose homeostasis traits (SI, AIRg,
DI) were tested using mixed effect, general linear regres-
sion models implemented in SPSS v.12 for Windows
(SPSS Inc., Chicago, IL). Skewed variables were ln-trans-
formed to normality prior to analysis, and age, body mass
index (BMI), gender, genotype, protocol (tolbutamide or
insulin), and diagnosis (IGT or glucose tolerant) were
included as factors and covariates, as appropriate. Pedi-
gree membership was included as a random factor in anal-
yses of family-based Utah samples.
ARNT expression was normalized to 18S RNA and both
pair-wise and group-wise differences compared using the
nonparametric Mann-Whitney U and Wilcoxan signed
rank tests. For allelic expression imbalance, we computed
the 95% CI for the assay from DNA (expected ratio 1:1).
We considered allelic expression imbalance to be present
if the ARNT RNA ratio fell outside the 95% CI for DNA in
heterozygous individuals. The significance for the number
of samples falling outside the 95% CI was determined
using a chi-square goodness of fit test.
Power considerations
We calculated the power assuming p < 0.05 and for odds
ratios over 1.5 (approximately that of TCF7L2) using
allelic association (approximately the same as the
Cochran Armitage trend test). We considered a control
minor allele frequency range of 0.1 to 0.4. Among our pri-
mary European American population, we had 70% power
at an odds ratio of 1.7 for a minor allele frequency of 0.1,
or over 70% power for an odds ratio of 1.6 or greater for
a minor allele frequency of 0.15 – 0.25, and over 70% for
a minor allele frequency over 0.25 at an odds ratio of 1.5.
Among African Americans, our power exceeded 70% for
an odds ratio over 1.5 at minor allele frequencies over
0.15, but would have required an odds ratio of 1.6 for
70% power at a minor allele frequency of 0.1.
Results
Association with type 2 diabetes
Results of both European American and African American
association studies are shown in Table 2, with raw geno-
type data shown in Table 3. No individual SNP was asso-
ciated with type 2 diabetes in either population, with the
best trend for rs10305685 in African Americans (p =
0.067; OR = 0.75). In the European American case-control
study, SNPs rs2134688 (intron 4) and rs4379678
(3'flanking) were in complete linkage disequilibrium (r2 =
1) despite selection on r2 < 0.9. Excess homozygosity for
the minor allele was observed in controls for both SNPs,
with evidence for a protective effect of the rare
homozygous alleles (p = 0.006; Table 3). We expanded
SNP rs2134688 into an independent European American
Table 2: Summary of single nucleotide polymorphisms and allele frequencies
Position RS Number Genome Location Variant Gene Location Caucasian Case/
Control Frequency
African – American 
Case/Control Frequency
-992 rs7517566 149116659 C/T 5' Flanking ND1 0.138/0.17
7377 rs11204735 149108291 G/A Intron 1 0.432/0.448 0.164/0.1693
32158 rs2134688 149083510 T/C Intron 4 0.087/0.086 NP
34242 rs10305679 149081426 T/C Intron 5 NP 0.194/0.221
38039 rs10305685 149077629 A/G Intron 6 NP 0.158/0.201
39928 rs10305695 149075740 G/A Intron 6 0.032/0.041 NP
40155 rs2228099 149075513 G/C Exon 7 (Val to Val) ND2 ND2
46017 rs10305710 149069651 G/A Intron 10 0.041/0.059 NP
47578 rs3738483 149068090 G/A Intron 12 ND1 0.322/0.348
48389 rs10305714 149067279 T/C Intron 12 0.324/0.344 0.265/0.232
49289 rs1889740 149066379 G/A Intron 12 0.345/0.363 0.481/0.466
50312 rs10305718 149065356 C/G Intron 13 NP 0.189/0.173
53679 rs10305724 149061989 C/T Intron 14 0.061/0.041 NP
56428 rs11589458 149059240 T/C Intron 14 ND 0.22/0.192
65586 rs10305751 149050082 G/A 3'UTR < 0.05 0.124/0.133
66247 rs10847 149049421 G/A 3'UTR 0.28/0.319 < 0.05
68462 rs4379678 149047206 A/G 3' Flanking/Intron 1 of 
CTSK
0.087/0.085 NP
Position is given relative to the A of the ATG start site. Genome location is based on the March 2006 (hg18) build. Variant is given for the negative 
(coding) strand as major/minor allele in Caucasian samples. Frequencies are given for the minor allele in Caucasian and African American samples. 
NP, not polymorphic in HapMap dataset; ND, not done. 1 r2 = 1 with rs2134688; 2, r2 = 1 with rs1889740; 3 minor allele is "G" in African Americans.BMC Medical Genetics 2008, 9:16 http://www.biomedcentral.com/1471-2350/9/16
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case-control cohort ascertained in Arkansas, where no
trend to an association with type 2 diabetes was observed
(Table 3).
Screening of the ARNT gene for additional variants identi-
fied a single synonymous SNP in exon 7, previously
reported as rs2228099. Our selected tagSNP rs1889740,
which showed no association with type 2 diabetes in
European American or African American populations, was
a perfect proxy (r2 = 1) in both HapMap CEPH and Yoru-
ban populations. We confirmed the strong linkage dise-
quilibrium in 120 European American individuals. We
confirmed also the presence of common SNPs rs7517566
in the 5' flanking region, rs35756904 in the 5' untrans-
lated region, rs10305650 in intron 1, rs2256355 and
rs1027699 in intron 6, rs3738483 and rs3768017 in
intron 12,, and rs10305749 in the 3' untranslated region.
Each common variant was typed directly or tagged by a
typed SNP at r2 > 0.9, and neither the typed SNPs nor
excellent proxies were associated with type 2 diabetes. We
also identified a very rare SNP (rs7515228; 1 hetero-
zygous individual in 48 samples) in the 5' flanking region,
which was not typed due to low power in our population.
In European Americans, 8/9 SNPs were confirmed to have
a minor allele frequency over 5%, and all 8 SNPs fell
within a single block using the solid spline block defini-
tions [12]. The 8 SNPs defined 7 common haplotypes, of
which none differed significantly in frequency between
cases and controls (Table 4). Similarly, among the African
American population all 10 tagSNPs fell within a single
block. Haplotype "CTGTTCGCAC" was more common
among controls (6.7%) than among cases (3.6%), as was
a 4 marker sliding window (ATAC; 50.3% in cases vs
43.8% in controls, p = 0.038). Neither nominal associa-
tion remained significant on permutation testing (Table
5).
ARNT SNPs and insulin secretion
Based on the proposed role of ARNT in insulin secretion
[3], we selected 4 SNPs that showed a trend to an associa-
tion with type 2 diabetes or that had a minor allele fre-
quency over 10% to test in two populations of
nondiabetic European American individuals who had
undergone detailed phenotyping of insulin sensitivity and
secretion. Both rs188970 (p = 0.005) and rs11204735 (p
= 0.002) were associated with AIRg in nondiabetic mem-
bers of high risk Utah families. However, neither finding
was replicated in and unrelated European American sam-
ple from Arkansas. Disposition index (DI), a measure of
the ability of the β-cell to compensate for insulin resist-
ance, was associated with rs2134688 in unrelated individ-
uals from Arkansas in interaction with both body mass
index (p = 0.004) and age (p = 0.04). Marginal means for
all analyses are shown in Table 6. Because ARNT null mice
showed sexual dimorphism in effects on insulin secretion,
Table 3: Raw counts of cases and controls by genotype for ARNT region SNPs in Caucasians and African Americans
Position RS number Population Variant Control Type 2 Diabetes
DD Dd dd DD Dd dd
-992 rs7517566 AA C/T 132 53 6 276 86 8
7377 rs11204735 UT
AA
G/A
A/G
60
129
81
61
41
2
60
260
96
102
34
10
32158 rs2134688 UT
AR
T/C
T/C
158
167
17
24
7
2
157
176
33
37
0
3
34242 rs10305679 AA T/C 116 64 10 243 112 16
38039 rs10305685 AA A/G 122 63 7 264 95 11
39928 rs10305695 UT G/A 169 11 2 179 12 0
46017 rs10305710 UT C/T 158 19 1 171 11 2
47578 rs3738483 AA C/T 84 81 26 175 152 43
48389 rs10305714 UT
AA
T/C
T/C
82
114
74
65
26
12
86
201
82
142
20
27
49289 rs1889740 UT
AA
C/T
C/T
78
58
76
87
28
45
83
102
83
179
24
88
50312 rs10305718 AA G/C 130 56 5 247 108 16
53679 rs10305724 UT C/T 170 9 3 168 23 0
56428 rs11589458 AA T/C 128 56 9 230 119 22
65586 rs10305751 AA C/T 142 49 1 289 74 9
66247 rs10847 UT C/T 88 74 21 102 68 19
68462 rs4379678 UT T/C 158 17 7 157 33 0
Position is shown relative to ATG start site. Variants are shown for the major/minor allele, as genotyped. Populations are as described in Table 1: 
UT, Utah Caucasian; AR, Arkansas Caucasian; AA, African-American. The total number of samples genoytped varies due to genotyping success 
rates, and may differ from the totals in Table 1.BMC Medical Genetics 2008, 9:16 http://www.biomedcentral.com/1471-2350/9/16
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we also tested for an interaction of genotype with gender.
Rs2134688 showed a significantly lower mean DI among
women (0.228) than men (4.822; p = 0.001) among Utah
family members, but this interaction was not observed in
individuals from Arkansas (data not shown).
ARNT gene expression
ARNT mRNA levels in transformed lymphocytes did not
differ between 8 European American control individuals
and cell lines from their 8 type 2 diabetic siblings, either
when grown under normoglycemic conditions (ARNT to
18 S RNA ratio 0.958, range 0.611–1.285 in controls vs
1.067, range 0.446 – 1.555 in diabetic cell lines; p = 0.40)
or when cultured in 28 mM glucose and 5 nmol/l insulin
(0.8131.067, range 0.449–1.164 in controls; 0.946, range
0.400 – 2.329 in type 2 diabetes; p = 0.67).
We searched for evidence of cis-acting regulatory variants
by testing the ratio of ARNT transcripts (cDNA) in trans-
formed lymphocytes from European American and Afri-
can American individuals who were heterozygous for the
transcribed variants rs2228099 and rs10847 (Figure 4).
We compared cDNA from 11 individuals at rs10847 to
154 DNA samples, and 23 cDNA samples at rs228099 to
63 DNA samples. Both SNPs showed some evidence of
allelic expression imbalance, with 4/11 samples for
rs10847 and 7/23 for rs228099 falling outside of the 95%
confidence intervals for the allelic ratio set from the cDNA
(p = 0.0001 and p = 0.001, respectively). At rs10847, sam-
ples showed allelic ratios of 1.6 to 3.0 (expected 1.14 from
DNA), whereas deviations from expectations were modest
for rs228099 (ratios 1.18–1.21, expected 1.07; Figure 4).
A single sample at rs228099 showed a ratio in the oppo-
site direction (ratio 0.41).
Discussion
ARNT (or HIF1β) is the obligate heterodimer for a family
of bHLH-PAS transcription factors that include HIF1α,
HIF2α and AhR. These proteins in turn mediate signal
transduction in response to both hypoxia and environ-
mental toxins, including dioxin and polycyclic aromatic
hydrocarbons [3]. Recent data have also implicated ARNT
in regulation of important downstream genes in the β-
cell, including HNF4α, IRS2, AKT2, and enzymes of the
glycolytic pathway [3]. Indeed, putative ARNT binding
sites may exceed 13,000 in the genome [3], and may
include genes involved in glucose metabolism, vascular
function, and oxygen transport (erythropoietin). Genes
downstream of ARNT such as HNF4α may in turn bind to
large numbers of promoters [19]. In addition to data sup-
porting ARNT as a strong functional candidate gene for
type 2 diabetes, the ARNT gene is located on human chro-
mosome 1q21, a region with replicated linkage to type 2
diabetes in diverse populations. These facts suggested that
genetic variants altering ARNT  function or regulation
would impact glucose homeostasis and diabetes risk. To
test this hypothesis we searched for indirect evidence that
SNPs marking common haplotypes were associated with
type 2 diabetes or altered insulin secretion. We also
searched directly for coding or highly conserved variants
that might directly impact ARNT function.
In the current study, we found no nonsynonymous SNPs
that were likely to alter ARNT function. Based on HapMap
data and our own genotyping, the selected tagSNPs
should have adequately covered all common genetic vari-
ants. No SNP showed an allelic association with type 2
diabetes, either European American or African American
individuals. Although we found associations of SNPs
rs2134688 (intron 4) and rs4379678 (3' flanking region)
under a recessive model, these findings could not be con-
firmed in a larger population and we believe the original
observations, which were also out of Hardy Weinberg
Equilibrium, were likely spurious and due to small sam-
ple size. We anticipated that variation in ARNT would
alter insulin secretion, and we indeed found evidence for
an association of SNPs rs188970 (a perfect proxy for syn-
onymous SNP rs2228099) and rs11204735, with altered
AIRg among members of high risk families. On the other
Table 4: Haplotype Frequencies for ARNT SNPs in Utah 
Caucasian Cases and Controls
Haplotype Case Frequency Control frequency P Value
TCCTCCTA 0.324 0.340 0.624
TTCCTCTG 0.282 0.319 0.280
TCCCTCTG 0.185 0.133 0.055
CCCCTCCA 0.087 0.085 0.935
TCTCTCTG 0.061 0.041 0.232
TCCCTTTG 0.041 0.056 0.324
TCCTTCTA 0.021 0.022 0.928
The 8 marker haplotypes are shown for all markers with minor allele 
frequency over 5%. The bases are shown according to the assay and 
may be the complement to the nucleotide in the public database. The 
SNPs included were rs4379678, rs10847, rs10305724, rs1889740, 
rs10305714, rs10305710, rs2134688, rs11204735.
Table 5: Haplotype frequencies for ARNT SNPs in African 
American cases and controls
Haplotype Case Frequency Control Frequency P Value
ATAC 0.503 0.438 0.038
GCAC 0.157 0.199 0.076
ATGC 0.164 0.170 0.820
ATAT 0.138 0.170 0.163
ACAC 0.037 0.023 0.224
Four marker haplotypes are shown using markers rs10305685, 
rs10305679, rs11204735, and rs7517566. Haplotypes are shown with 
the nucleotide as genotyped in the assay, which may differ from the 
nucleotide listed in public databases.BMC Medical Genetics 2008, 9:16 http://www.biomedcentral.com/1471-2350/9/16
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hand, these findings were not replicated in a separate and
differently ascertained population from Arkansas. The
lack of replication may reflect differences in the two pop-
ulations – one cohort of related individuals from high risk
families, the other a more heterogeneous and unrelated
population from Arkansas with more obese subjects and a
very different environment. Alternatively, the observation
in high risk families may have been spurious, as we tested
Table 6: Marginal means for intravenous glucose tolerance measures
SNP Utah Caucasian Family samples Arkansas Caucasian population
rs10847 CC CT TT p-value CC CT TT p-value
n 68 47 10 124 85 21
SI 5.66 
(4.29,7.48)
6.14 
(4.64,8.11)
7.75 
(1.84,32.64)
0.84 4.85 (4.11, 
5.71)
5.45 (4.47, 
6.63)
5.42 (3.58, 
8.18)
0.64
AIRg 116 (93,145) 152 (122,190) 249 (81,757) 0.09 2370 
(2082,2694))
2142 
(1830,2502)
1890 
(1380,2580)
0.32
DI 0.99 
(0.59,1.66)
1.29 
(0.77,2.16)
1.55 
(0.42,5.68)
0.5 1152 
(969,1371)
1173 
(951,1447)
1111 
(716,1725)
0.37
rs188970 CC CT TT p-value CC CT TT p-value
n 48 51 23 87 103 32
SI 5.29 
(4.11,6.81)
6.40 
(4.83,8.46)
6.45 
(4.27,9.73)
0.49 5.68 (5.07, 
6.37)
5.40 (4.85, 
6.00)
5.70 (4.68, 
6.93)
0.11
AIRg 200 
(163,246)
141 
(113,177)
115 (82,159) 0.005 2388 
(2046,2784)
2082 
(1806,2400)
2664 (2052, 
3468)
0.18
DI 1.25 
(0.76,2.06)
1.13 
(0.65,1.97)
1.07 
(0.47,2.42)
0.91 1356 
(1170,1573)
1122 
(979,1287)
1520 
(1180,1958)
0.37
rs2134688 TT TC+CC p-value TT TC+CC p-value
n 96 26 193 36
SI 6.62 
(6.21,8.41)
5.80 (3.56,9.45) 0.86 5.48 
(5.05,6.37)
5.38 (4.43, 6.52) 0.86
AIRg 164 (134, 200) 132 (88, 197) 0.31 2244 
(2022,2490)
2280 (1788,2910) 0.66
DI 1.33 
(0.91,1.95)
1.07 (0.59,1.93) 0.5 1132 
(987,1299)
1201 (867,1633) 0.94
rs11204735 GG GA AA p-value GG GA AA p-value
n 34 53 31 66 115 48
SI 5.49 
(3.90,7.72)
6.28 
(4.70,8.39)
4.92 
(3.61,6.71)
0.46 5.60 (4.88, 
6.45)
5.22 (4.70, 
5.78)
5.52 (4.68, 
6.52)
0.66
AIRg 117 (89,152) 150 
(119,188)
216 
(169,277)
0.002 2370 
(1986,2832)
2220 
(1944,2538)
2190 
(1776,2700)
0.8
DI 0.71 
(0.38,132)
1.36 
(0.81,230)
1.36 
(0.78,2.38)
0.14 1328 
(1112,1587)
1157 
(1012,1322)
1209 
(980,1492)
0.46
Marginal means are shown after adjustment for age, gender and BMI; significance is based on a general linear model and p values are shown without 
correction for multiple testing. AIRg in the Utah Caucasian study is from the mean 2–10 min post challenge insulin excursion in pmol/l; for Arkansas 
Caucasian study, the AIRg is taken from MinMod Millenium output and is the area under the curve from 0 to 10 min, converted to pmol/l. All means 
are transformed back to the linear scale from Ln-transformed values; 95% confidence intervals are provided in parenthesis. SI, insulin sensitivity 
index from MinMod in (pmol/l) min-1; AIRg, acute 2–10 min insulin response to intravenous glucose bolus, in pmol/l (UT sample) or pmol-min/l (AR 
sample); DI, Disposition index (SI × AIRg) has no units. Values from the Utah sample are × 10-2. Note that the MinMod Millenium program calculates 
disposition index using the area under curve for AIRg and without the decimal places for SI (10-5 (pmol/l) min-1. Because calculations in the Utah 
population used mean 2 min – 10 min insulin to calculate AIRg and calculated SI × AIRg values were calculated using the legacy MinMod program and 
Arkansas samples using the MinMod Millenium program, the values between populations are not directly comparable.BMC Medical Genetics 2008, 9:16 http://www.biomedcentral.com/1471-2350/9/16
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3 traits and 4 SNPs. However, the suspected biology of
ARNT would suggest that environmental interactions may
differ across populations. The same arguments apply for
the interaction of SNP rs2134688 with gender to deter-
mine DI. Additional studies are needed to determine the
role of these variants in insulin secretion.
Replication of genetic associations, both with dichoto-
mous traits such as type 2 diabetes and quantitative traits
such as AIRg has been difficult with sample sizes that are
practical for individual laboratories. We have sought alter-
native methods based on comparison of ARNT expression
among siblings discordant for type 2 diabetes, and using
allelic expression imbalance for transcribed SNPs to find
evidence for regulatory variants [13]. In the current study,
we examined two transcribed SNPs. In both cases, a few
heterozygous individuals showed allelic imbalance out-
side of the range observed for genomic DNA (Figure 2),
suggesting a possible regulatory mutation. Whether these
results in transformed lymphocytes reflect expression in
pancreatic β-cells is unknown, and the two SNPs appear to
give different results. Nonetheless, SNP rs2228099 is in
strong linkage disequilibrium with the SNP rs188970 that
was associated with altered insulin secretion.
The strengths of this study are the use of multiple
approaches to examine the ARNT gene, including associa-
tion studies in two populations, quantitative trait studies
for insulin secretion, and gene expression studies in trans-
formed lymphocytes as a surrogate tissue for pancreatic β-
cells. Nonetheless, this study had several limitations. First,
the association study was of modest size, and would have
been unable to detect a role for variants with small effect.
Recent genome wide association scans in type 2 diabetes
[20-23] have suggested that most if not all loci had odds
ratios (ORs) below 1.5 and generally near 1.2 or less.
Whereas we had 70% power to detect an association for
common SNPs with an OR in the range of 1.5–1.7, or the
approximate effect of the TCF7L2 gene [24], we had very
limited power to detect effects with an OR of 1.2 or less.
Although data for most published genome wide associa-
tion scans are not yet publicly available, the Diabetes
Genome Initiative scan [23] data are publicly available,
and show 3 SNPs in the ARNT gene that can be estimated
to capture 50% of the genetic variation. As with our study,
no SNP showed any trend to association in over 1400
cases and 1400 controls. Based on allelic association and
p < 0.05, the two SNPs at 35% minor allele frequency had
87% power to exclude an odds ratio of 1.2 or greater. That
effect size would be comparable to the role of known dia-
betes genes including the potassium channel gene
Allelic expression imbalance at 3'UTR (rs10847) and exonic (rs2228099) SNPs of the ARNT gene Figure 4
Allelic expression imbalance at 3'UTR (rs10847) and exonic (rs2228099) SNPs of the ARNT gene. The scatter 
plot shows the allele specific expression in cDNA () as compared to genomic DNA () for 11 heterozygous samples at 
rs10847 (C/T) and 23 heterozygous samples at rs2228099 (C/G).BMC Medical Genetics 2008, 9:16 http://www.biomedcentral.com/1471-2350/9/16
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KCNJ11 E23K variant, or peroxisome proliferator activat-
ing receptor γ (PPARG) P12A variant, or more recently
described variants that have required very large popula-
tions to confirm [20-23,25]. Hence, our failure to detect
an association with type 2 diabetes in our more modest
sample size (albeit with two separately examined study
populations) probably did not result from SNPs of small
effect size.
Small effects on insulin secretion similarly would not
have been detectable in populations of a size that could be
examined with detailed phenotyping, as was done in our
study. Thus, additional ARNT variants might have a small
effect on insulin secretion that we did not detect, or might
have an effect on aspects of insulin secretion that we did
not measure. Finally, we did not exhaustively screen the
ARNT gene for variants, but instead used a combination
of screening conserved regions and indirect screening
based on linkage disequilibrium relationships to test the
common variants. Although unlikely, a causative SNP
outside of the region screened and not in linkage disequi-
librium with our tagSNPs might have gone undetected.
Conclusion
Gunton et al. [3] observed a 90% decrease in ARNT
expression in pancreatic islets from type 2 diabetic indi-
viduals when compared with nondiabetic islets. In con-
trast, we found no difference in ARNT  message in
transformed lymphocytes from siblings with type diabetes
and nondiabetic siblings. Our results may reflect the lack
of correspondence of gene expression in transformed lym-
phocytes and β-cells, or Gunton et al may have found
expression changes that were secondary to hyperglycemia.
Our data provide some evidence that ARNT variants may
alter insulin secretion and that ARNT gene variants may
alter transcript levels, but our findings are not compatible
with the dramatic differences in transcript levels observed
by Gunton et al. We suggest that such striking reductions
in  ARNT  transcript levels in the diabetic pancreas are
unlikely to be caused by genetic variants and thus not the
direct cause of the insulin secretory defect that occurs early
in type 2 diabetes and progresses throughout the disease.
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